Aruni Ghose: Systematic review on exosomal biomolecules as noninvasive biomarkers in Prostate Cancer
Aruni Ghose, Co-Founder and Chief Medical Officer of OncoFlow, shared an article he and colleagues authored on LinkedIn:
“Hot off the Press!!
Our systematic review looked at exosomal biomolecules as noninvasive biomarkers for the diagnosis, prognosis, and treatment response in Prostate Cancer. Exosomes in blood and urine of prostate cancer patients, including microRNAs (miRNAs), proteins, and lipids, demonstrate disease-specific changes.
These can differentiate between malignant and benign hyperplasia of the prostate, predict disease aggressiveness, and monitor treatment efficacy. MiRNA emerged as the most frequently studied biomolecule, demonstrating superior diagnostic potential compared to traditional methods like prostate-specific antigen (PSA) testing.
Great collaborative piece between Medway NHS Foundation Trust, Medway NHSFT Research and Innovation Team, Kent and Medway Medical School, University of Kent, Canterbury Christ Church University, King’s College London and University of Greenwich – Muhammad Yameen Hamid, Rukhshana Rabbani Dina, Rakkan Afsara Tushi, Samarea Nowrin, Konstantinos Sirlantzis, Saak Ovsepian, Stergios Boussios.”
Authors: Yameen Hamid et al.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023